557 related articles for article (PubMed ID: 28639969)
1. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
[TBL] [Abstract][Full Text] [Related]
3. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?
Keohane J; O'Mahony C; O'Mahony L; O'Mahony S; Quigley EM; Shanahan F
Am J Gastroenterol; 2010 Aug; 105(8):1788, 1789-94; quiz 1795. PubMed ID: 20389294
[TBL] [Abstract][Full Text] [Related]
4. Presence of Irritable Bowel Syndrome Symptoms in Quiescent Inflammatory Bowel Disease Is Associated with High Rate of Anxiety and Depression.
Perera LP; Radigan M; Guilday C; Banerjee I; Eastwood D; Babygirija R; Massey BT
Dig Dis Sci; 2019 Jul; 64(7):1923-1928. PubMed ID: 30725303
[TBL] [Abstract][Full Text] [Related]
5. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission.
Jonefjäll B; Strid H; Ohman L; Svedlund J; Bergstedt A; Simren M
Neurogastroenterol Motil; 2013 Sep; 25(9):756-e578. PubMed ID: 23731196
[TBL] [Abstract][Full Text] [Related]
6. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
[TBL] [Abstract][Full Text] [Related]
7. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
8. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
Sydora MJ; Sydora BC; Fedorak RN
J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
[TBL] [Abstract][Full Text] [Related]
9. Patients with longstanding ulcerative colitis in remission do not have more irritable bowel syndrome-like symptoms than controls.
Lundgren D; Rutegård J; Eklöf V; Palmqvist R; Karling P
BMC Gastroenterol; 2016 Nov; 16(1):139. PubMed ID: 27881072
[TBL] [Abstract][Full Text] [Related]
10. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
[TBL] [Abstract][Full Text] [Related]
11. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis.
Halpin SJ; Ford AC
Am J Gastroenterol; 2012 Oct; 107(10):1474-82. PubMed ID: 22929759
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners.
Abdalla MI; Sandler RS; Kappelman MD; Martin CF; Chen W; Anton K; Long MD
Inflamm Bowel Dis; 2017 Feb; 23(2):325-331. PubMed ID: 28092305
[TBL] [Abstract][Full Text] [Related]
14. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
[TBL] [Abstract][Full Text] [Related]
15. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
[TBL] [Abstract][Full Text] [Related]
16. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
[TBL] [Abstract][Full Text] [Related]
17. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy.
Long MD; Drossman DA
Am J Gastroenterol; 2010 Aug; 105(8):1796-8. PubMed ID: 20686466
[TBL] [Abstract][Full Text] [Related]
19. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
[TBL] [Abstract][Full Text] [Related]
20. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome.
Campbell JP; Zierold C; Rode AM; Blocki FA; Vaughn BP
J Clin Gastroenterol; 2021 Mar; 55(3):239-243. PubMed ID: 32324678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
